About 

Inflexion is backing Upperton Pharma Solutions, a UK-based specialist contract development and manufacturing organisation, to extend its services into later-stage clinical trials and niche-scale commercial manufacturing.

Upperton’s particle engineering expertise has enabled it to develop a wide range of finished dosage formats for its pharmaceutical clients, typically during early-phase clinical trials. It is known for its spray drying expertise, a particle engineering technology used to ensure targeted delivery of drugs to the lungs and nasal cavity or provide solutions to pharma clients who have challenges with poorly soluble molecules. The business received the King’s Award for International Trade in 2023.

Value acceleration 

Inflexion is supporting Upperton to expand its scale and capabilities. Within 18 months of Inflexion’s investment, the business doubled its headcount, and in 2024 it opened a new purpose-built 50,000 sq ft facility, Trent Gateway, increasing manufacturing space 10-fold and analytical space four-fold. A new aseptic fill facility has also been commissioned to accelerate Upperton’s growth into other hard-to-formulate technologies. Inflexion has supported additions to the C-suite and is also evaluating M&A targets with strong strategic rationale.